Table 1.

Adverse events.

	Tislelizumab (N = 70)
	TEAE		TRAE
N (%)	All grades	Grade ≥3	All grades	Grade ≥3
Patients with ≥1 AE	68 (97.1)	29 (41.4)	68 (97.1)	22 (31.4)
Pyrexia	40 (57.1)	0	38 (54.3)	0
Upper respiratory tract infection	27 (38.6)	2 (2.9)	17 (24.3)	0
Hypothyroidism	26 (37.1)	0	26 (37.1)	0
Weight increased	24 (34.3)	2 (2.9)	19 (27.1)	2 (2.9)
White blood cell count decreased	15 (21.4)	1 (1.4)	14 (20.0)	0
Cough	15 (21.4)	0	9 (12.9)	0
Alanine aminotransferase increased	14 (20.0)	0	14 (20.0)	0
Pruritus	13 (18.6)	0	12 (17.1)	0
Weight decreased	12 (17.1)	0	8 (11.4)	0
Aspartate aminotransferase increased	11 (15.7)	0	8 (11.4)	0
Rash	11 (15.7)	1 (1.4)	11 (15.7)	1 (1.4)
Neutrophil count decreased	10 (14.3)	2 (2.9)	9 (12.9)	1 (1.4)
Hyperuricemia	10 (14.3)	0	7 (10.0)	0
Diarrhea	10 (14.3)	0	6 (8.6)	0
Anemia	9 (12.9)	1 (1.4)	4 (5.7)	0
Blood creatine phosphokinase increased	8 (11.4)	2 (2.9)	8 (11.4)	2 (2.9)
Blood thyroid stimulating hormone increased	8 (11.4)	0	8 (11.4)	0
Blood bilirubin increased	7 (10.0)	0	7 (10.0)	0
Platelet count decreased	7 (10.0)	0	6 (8.6)	0
Pneumonia	7 (10.0)	2 (2.9)	6 (8.6)	1 (1.4)
Vomiting	7 (10.0)	0	5 (7.1)	0
Headache	7 (10.0)	1 (1.4)	5 (7.1)	1 (1.4)
Neutropenia	4 (5.7)	2 (2.9)	3 (4.3)	2 (2.9)
Hypertension	3 (4.3)	2 (2.9)	3 (4.3)	2 (2.9)
Lipase increased	2 (2.9)	2 (2.9)	2 (2.9)	2 (2.9)
Pneumonitis	2 (2.9)	2 (2.9)	2 (2.9)	2 (2.9)

Note: All grades include AEs reported in ≥10% of patients; grade ≥3 events include those reported in ≥2% of patients. AE, adverse event; TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event.